Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease
Potential Once-Yearly Regimen
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
